Article and Video CATEGORIES

Cancer Journey

Search By

 

Dr. Aakash Desai, MBBS, MPH serves as an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. His pioneering research is primarily concentrated in the realm of evidence-based oncology, clinical trials, drug development, healthcare delivery, and quality of cancer care. He holds a particular interest in Thoracic Oncology and drug development.

Click here for more information about Dr. Desai. 

 

Leading Developments and Current Questions in Lung Cancer Panel Discussions
Drs. Desai and Abu Rous discuss emerging information and trial data as presented at ASCO 2024.
Author
Aakash Desai, MD, MPH - Guest Faculty
Image
Trial data ASCO 2024

In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO.

To watch the complete playlist, click here. 

 

 

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora